Synopsis Rare cancers are defined based on their incidence rate which is fewer than six per 100,000 people. They are represented by 50% of the female with genital tract tumors and 25% of all cancer deaths. Rare tumors are often misdiagnosed and lead to a delayed diagnosis that impacts the timing of treatment. Limited information on evidence-based treatment and lack of established treatment guidelines for rare cancers make it challenging due to their diverse biological behaviors.
For rare gynecologic cancer, standard therapeutic approaches still remain challenging due to their lower prevalence rate. In the recent past, incorporation of genomic characterization in the routine clinical care of different tumor types has become a standard. However, for rare tumors, this needs further investigation. The present study demonstrates the feasibility of incorporating precision medicine in patients…
